Lipoproteins Impact Increasing Cardiovascular Mortality

Umbrasienė, Jelena; Babarskienė, Rūta-Marija; Venclovienė, Jonė

doi:10.5772/48124

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute coronary syndrome (ACS) is the most frequent cause of the death in all cardiovascular diseases [ 1 ]. It is argued that despite readily available and highly effective treatment the mortality rates in ACS patients are still very high [ 2 , 3 ]. The ACS treatment guidelines have recommended that drugs for primary and secondary prevention should consist of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptors blockers (ARBs) if ACE inhibitors are not tolerated, β-blockers (BB), statins and antiaggregants (low dose aspirin or clopidogrel) [ 1 , 2 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Does Treatment Impact Health Outcomes for Patients After Acute Coronary Syndrome?

Umbrasienė

Vanagas

Vencloviene

2015

IJERPH

View full text Add to dashboard Cite

Background: Mortality rates for acute coronary syndrome (ACS) patients are still very high all over the world. Our study aimed to investigate the impact of ACS treatment on cardiovascular (CV) mortality eight years following ACS. Methods: A retrospective cohort study with a total of 613 patients was used. The data was collected from databases and medical records. An evidence-based treatment (EBT) algorithm was used based on the ESC guidelines. Logistic regression analysis and standardized odds ratios with 95% confidence interval (CI) were used for the risk assessment, with a p level < 0.05 considered as significant. Results: The median follow-up time in this study was 7.6 years. During follow-up 48.9% of the patients (n = 300) died from CV and 207 (69%) for a relevant reason. For monotherapy ACE inhibitors and β-blockers, and for fixed dose combined drugs ACE inhibitors and diuretics, were most frequently used. EBT was provided to 37.8% of patients. The EBT use (HR 0.541, CI 0.394–0.742, p < 0.001) during follow-up period was important for reducing CV mortality in ACS patients. Conclusions: The combined use of EBT significantly improved outcomes. The recurrent myocardial infarction and percutaneous coronary intervention patients were more frequent in EBT and it was beneficial for reducing CV mortality.

show abstract